NEW YORK (GenomeWeb) – Several independent researchers last week shared promising results of their work using the genome-editing tool CRISPR/Cas9 to advance treatments for Duchenne muscular dystrophy.

In a group of three studies published in the Jan. 1 issue of Science, researchers found that after viral delivery into muscle tissue or blood, CRISPR/Cas9 was able to excise disease-associated exons from the dystrophin gene, and improve the symptoms of mice with a rodent version of the disease.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.